In a murine melanoma model, MLP, combined with an anti-PD-1 antibody, significantly enhanced CD8+ T-cell responses and improved survival compared to monotherapies, demonstrating synergistic effects in overcoming immune resistance (29). The gene discussed is PDCD1; the disease is melanoma.